Screener
Alto Neuroscience ANRO Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001999480-26-000012
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Loss on debt extinguishment | — | (681) |
| Other, net | (115) | (41) |
| Total other income, net | 901 | 507 |
| Net loss | $(26,237) | $(15,169) |
| Other comprehensive income (loss): | ||
| Change in fair value attributable to instrument specific credit risk | 7 | 134 |
| Foreign currency translation | (16) | (19) |
| Total other comprehensive income (loss) | (9) | 115 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Alto Neuroscience's net income?
- Alto Neuroscience (ANRO) reported net income of -$26.24M in Q1 2026.
- How has Alto Neuroscience's net income changed year-over-year?
- Alto Neuroscience's net income decreased by 73.0% year-over-year, from -$15.17M to -$26.24M.
- What is the long-term trend for Alto Neuroscience's net income?
- Over 2 years (2023 to 2025), Alto Neuroscience's net income has grown at a 32.0% compound annual growth rate (CAGR), from -$36.31M to -$63.24M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Alto Neuroscience's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude